Epigenetic factors, including altered microRNA (miRNA) expression, may contribute to aberrant immune cell function in systemic lupus erythematosus (SLE). MiRNA-let-7a (let-7a) has been shown to directly alter cell cycle progression and proinflammatory cytokine production. Due to the crucial role of let-7a in cell division and inflammation, we investigated let-7a-mediated proliferation and NFkB translocation in J774A.1 macrophages and MES 13 mesangial cells in vitro. In immune-stimulated cells transfected with let-7a, cell proliferation was significantly increased over time. There was a significant increase in the number of immune-stimulated cells in S and G 2 phases. Immune-stimulated cells overexpressing let-7a had increased nuclear translocation of NFkB. Bioinformatical analysis revealed that the E2F family, critical regulators of the G 1 -S transition, has potential binding sites for let-7a in their mRNA transcripts. Let-7a overexpression significantly increased the expression of the cell cycle activator E2F2 and increased retinoblastoma protein (Rb) phosphorylation in immune-stimulated cells. The cell cycle inhibitor E2F5 was significantly decreased in let-7a-transfected cells that were immune-stimulated. Bioinformatical analysis revealed E2F2 and NFkB are transcription factors predicted to regulate the let-7a promoter. We analyzed transcriptional regulation of let-7a by real-time RT-PCR using chromatin immunoprecipitation with E2F2 and NFkB antibodies. There was an increase in E2F2 and NFkB binding in DNA enriched for the let-7a promoter in immune-stimulated cells. Silencing E2F2 or NFkB significantly decreased let-7a expression and IL-6 production in immune-stimulated cells. Taken together, our results suggest that overexpression of let-7a may contribute to hyperplasia and the proinflammatory response in SLE.
INTRODUCTION
Abnormal macrophage and mesangial cell function have been shown to contribute to systemic lupus erythematosus (SLE) pathogenesis in lupus mouse models and patients with glomerulonephritis.
1-4 SLE is a complex autoimmune disease characterized by high titers of autoantibodies against nuclear antigens.
5 Due to endosomal trafficking, nuclear antigens trigger intracellular Toll-like receptors, activating the canonical NFkB pathway. 6 The deposition of immune complexes in the renal glomeruli activates mesangial cells, the principle immunoregulatory cell in the glomerulus. Activated mesangial cells produce inflammatory and chemotactic mediators that target the kidney for monocyte, neutrophil, and lymphocyte infiltration. 3, 7, 8 Activated mesangial cells and macrophages produce proinflammatory cytokines and chemokines that induce the maturation and activation of infiltrating T cells. T cells perpetuate the activation of innate immune cells and the B cell response. In lupus nephritis (LN), the sustained inflammatory response results in pathological features including cell proliferation, inflammatory cell infiltration, sclerosis, and fibrosis. 9 Cytokines and other stimuli induce the activation of the NFkB family of transcription factors, which translocate into the nucleus to transcribe a variety of genes involved in inflammation, immune regulation, and apoptosis. 10 The NFkB p65 (RelA) subunit, along with c-Rel and RelB, contains a transcription activation domain allowing it to positively regulate gene expression. 11 Activated NFkB transcribes genes encoding proinflammatory cytokines like IL-6 that can continue to increase NFkB activation via autocrine signaling. 12, 13 Elevated levels of IL-6 have been observed in the sera and tissues of SLE patients.
14 Renal IL-6 expression is positively correlated with increased mesangial proliferation, tubulointerstitial damage, and lymphocyte infiltration. 15 In SLE, mesangial cells are hyperresponsive to immune stimulation; when activated by proinflammatory mediators like IL-6, mesangial cells produce growth factors and cytokines that stimulate extracellular matrix deposition, a pathological characteristic that is increased in glomerular diseases. [16] [17] [18] Because cell proliferation is a common histological feature of LN, cell cycle regulators may contribute to SLE pathogenesis. [19] [20] [21] The E2F family of transcription factors plays a critical role in the regulation of the G 1 -S transition and can be subdivided into repressors and activators. 22 Repressor E2Fs (such as E2F5) occupy E2F target promoters during quiescence and in early G 1 phase. As cells enter late G 1 phase, the repressor E2F complexes are replaced by activator E2Fs (such as E2F2) that have been released from retinoblastoma protein (Rb) due to its phosphorylation. 23 E2F transcription factors regulate the expression of numerous genes needed for cell cycle entry and DNA synthesis. 24 A genome-wide association study in peripheral blood mononuclear cells from SLE patients found that a significant number of SLE-associated genes contain E2F-binding motifs in their promoters, which suggests transcription factors that regulate proliferation may play a role in SLE pathogenesis. 25 Epigenetics, including microRNA (miRNA) regulation, refers to stable and heritable changes in gene expression that are not dependent on DNA sequence. 26 MiRNAs are small, non-coding RNAs that function as endogenous regulators of gene expression by incompletely binding to the 39 untranslated region (UTR) of target mRNAs. 27 MiRNA expression is highly sensitive to inflammatory stimulation; lipopolysaccharide (LPS) induces the expression of miR-9, miR-132, miR-146, miR-147, miR-155, and miR-let-7a (let-7a) by activating transcription factors that regulate miRNA expression. [28] [29] [30] [31] [32] [33] MiRNAs can contribute to the proinflammatory environment by inducing the expression of proinflammatory cytokines, perpetuating the magnitude and duration of the immune response. 34, 35 Let-7a is implicated in SLE pathogenesis due to its responsiveness to immune stimulation and its reported inflammatory targets; the expression of let-7a is increased after LPS stimulation and it is overexpressed in the kidneys of SLE patients and the mesangial cells of lupus mice. 33, 36 In addition to their vast role in immunology, miRNAs have been shown to contribute to alterations in the cell cycle. 37, 38 Let7a targets the mRNA transcripts of transcription factors including E2F2 and c-myc as well as the transcripts of cell cycle regulatory proteins such as cyclin D2 and Ras. [39] [40] [41] [42] Although it has recently been shown that miRNAs play a critical role in SLE pathogenesis, the precise mechanisms are largely unknown. In these studies, we used in vitro approaches to investigate let-7a-mediated alterations to cell proliferation through E2F activation and the proinflammatory response through NFkB translocation.
MATERIALS AND METHODS

Cell culture
A mouse macrophage cell line (J774A.1) and a mouse mesangial cell line (MES 13) were purchased from ATCC (Manassas, VA, USA). The cells were grown in 75-mm 2 culture flasks at 37 uC in 5% CO 2 . Macrophages were cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin (Cellgro, Manassas, VA, USA). During serum starvation, cells were given DMEM containing 1% FBS and 1% penicillinstreptomycin (Cellgro). Mesangial cells were cultured in a 3 : 1 mixture of DMEM and Ham's F12 medium with 14 mM HEPES, supplemented with 5% FBS and 1% penicillin-streptomycin solution (Cellgro). For serum-starving medium, FBS was absent from the complete growth medium. For immune stimulation, LPS (Sigma-Aldrich, St Louis, MO, USA) and IFN-c (Cedarlane Laboratories Limited, Burlington, NC, USA) were added to the complete medium at a final concentration of 1 mg/ml and 100 ng/ml, respectively. For IL-6 stimulation, recombinant IL-6 (eBioscience, San Diego, CA, USA) was added to the complete medium at a final concentration of 100 ng/ml. Experiments were performed from passages 9-15. All experimental conditions were run in triplicate.
MiRNA/siRNA transfection Macrophages were transfected with Lipofectamine 2000 transfection reagent according to the manufacturer's protocol (Life Technologies, Grand Island, NY, USA). Mesangial cells were transfected with TransIT-siQUEST transfection reagent according to the manufacturer's protocol (Mirus, Madison, WI, USA). The let-7a mimicking RNA was used to endogenously alter miRNA levels (Dharmacon RNAi Technologies, Lafayette, CO, USA). The E2F2 siRNA (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), NFkB p65 siRNA (Life Technologies), or IL-6 siRNA (Life Technologies) was used to endogenously alter RNA levels. The non-targeting control miRNA (Life Technologies) or si-GENOME control #1 (Santa Cruz Biotechnologies) was used as the control. Cells and supernatants were collected for analysis 24 h post-stimulation unless otherwise noted.
MTT assay
Cultured cells were plated in 96-well plates at 1310 4 cells/well and transfected for 24 h with either the non-targeting control or let-7a mimicking miRNA. Non-stimulated cells received fresh complete media daily. Immune-stimulated cells received complete media containing LPS/IFN-c 1-5 days post-transfection. Viable cells were measured 1-5 days post-stimulation according to the manufacturer's protocol (Life Technologies). The plate was read at 540 nM on a microplate spectrophotometer. Each condition was performed in triplicate.
Cell cycle analysis Cultured cells were plated in six-well plates at 1310 6 and serum-starved overnight to reset the population to G 0 phase. The cells were transfected with either the non-targeting control or let-7a mimicking RNA. The cells received either complete media or complete media containing LPS/IFN-c 24 h posttransfection. Cells were collected after 24 or 48 h as previously described. 43 Briefly, cells were collected and fixed overnight in 70% ethanol at 220 uC. The cells were resuspended at a final cell density of 1310 6 cells/ml in 13 PBS containing propidium iodide (40 mg/ml; Enzo Life Sciences, Farmingdale, NY, USA) and RNase (100 mg/ml; Amresco, Solon, OH, USA). The cell suspensions were incubated at 37 uC for 30 min prior to flow cytometric analysis. Populations in G 0 -G 1 , S, and G 2 -M phase were measured by flow cytometry (FACSCalibur; BD Biosciences, San Jose, CA, USA) and the data were analyzed using FlowJo software (Tree Star Inc., Ashland, OR, USA). Each condition was performed in triplicate.
Isolation of RNA and miRNAs RNA and miRNAs were isolated using the mirVana miRNA isolation kit according to the manufacturer's protocol (Applied Biosystems, Carlsbad, CA, USA). RNA and miRNAs were quantified on a spectrophotometer (Nanodrop; Thermo Scientific, Waltham, MA, USA) and stored at 280 uC.
Real-time RT-PCR Let-7a expression was measured by real-time RT-PCR using TaqMan MicroRNA assays according to the manufacturer's protocol (Applied Biosystems). The TaqMan Small RNA Assays were used according to the manufacturer's protocol (Applied Biosystems). E2F2, E2F5, and NFkB p65 expression were measured using TaqMan Gene Expression assays according to the manufacturer's protocol (Applied Biosystems). Data were analyzed using the comparative C T (DDC T ) method as previously described. 44 All samples were run in triplicate.
Bioinformatics analysis
A database search was performed as previously described to determine cell cycle-associated mRNAs whose 39 UTR contain binding sites for let-7a. 33 Computational analysis of the let-7a promoter The DNA sequence of let-7a was obtained from the National Center for Biotechnology Information (93 nucleotides from 48538179 to 48538272 on chromosome 13, Accession NR_029725.1). The promoter sequence (1-kb upstream of the let-7a sequence) was determined using the BLAT genome browser gateway (National Center for Biotechnology Information Assembly MGSCv37). The DNA sequence was then analyzed with PROMO software to identify putative binding sites for different transcription factors. 45, 46 E2F2 and NFkB binding sites upstream of the let-7a start site were identified.
Chromatin immunoprecipitation (ChIP)
The SimpleChIP Enzymatic Chromatin IP Kit was used for ChIP and DNA purification according to the manufacturer's protocol (Cell Signaling, Danvers, MA, USA). ChIP was performed using ChIP-validated E2F2 (Santa Cruz Biotechnologies) and NFkB p65 (Cell Signaling) antibodies. Normal rabbit IgG (Cell Signaling) served as the non-targeting control antibody. Each condition was performed in triplicate. The enrichment of let-7a promoter DNA sequences was analyzed by real-time RT-PCR. DNA was amplified using FAM-labeled primers complementary to the let-7a promoter. The PCR primers (E2F2 forward 59-GAGGCTTATAGCCCAGGTGTATCA-39 and E2F2 reverse 59-CCTGTGTAATGAGGGAAAAGAAAA-39; NFkB forward 59-GAAATGTTTGTGTGTGGTAGTCAG-39 and NFkB reverse 59-TCAGGGAATAAGGTTGCCTATCGC-39) were designed to amplify 120-135 bp fragments from selected genomic regions. All samples were run in triplicate.
Western blot
Nuclear extracts were purified using the Nuclear Extract Kit according to the manufacturer's protocol (Active Motif, Carlsbad, CA, USA). Protein concentration was determined using the Bradford protein assay and equal amounts of protein were resolved by electrophoresis onto a Criterion TGX gel (Bio-Rad, Hercules, CA, USA). The gel was transferred to a 0.45 mm nitrocellulose membrane, blocked with 5% non-fat milk and incubated overnight at 4 uC with antibodies specific to phosphorylated Rb (pRb) (#8516; Cell Signaling), Rb (#9313; Cell Signaling), E2F2 (sc-633; Santa Cruz Biotechnologies), E2F5 (sc-999; Santa Cruz Biotechnologies), pIkB (#5A5; Cell Signaling), IkB (#44D4; Cell Signaling), NFkB (#S536; Cell Signaling), or b-actin (Ambion; Life Technologies, Grand Island, NY, USA). The blot was visualized using the Amersham ECL Plus Western Blotting Detection System (GE Healthcare, Piscataway, NJ, USA). For multiple visualizations, the blot was stripped by gently shaking for 30 min at 50 uC in stripping buffer. The stripping buffer contained 20 ml of 10% sodium dodecyl sulfate (Sigma-Aldrich), 12.5 ml of 0.5 M Tris HCl (pH 6.8; Sigma-Aldrich) and 0.8 ml of 2-Mercaptoethanol (SigmaAldrich) mixed in 67.5 ml of distilled water. Western blots were quantified by densitometry using ImageJ software (National Institutes of Health, Bethesda, MD, USA). Blots were normalized using b-actin.
NFkB activation assay Nuclear extracts were purified using the Nuclear Extract Kit according to the manufacturer's protocol (Active Motif). To detect NFkB activation, the TransAM NFkB p65 transcription factor assay kit was used according to the manufacturer's protocol using (Active Motif). The plate was read at 450 nm on a Spectramax 340PC microplate spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). All samples were run in duplicate.
ELISA IL-6 protein levels in the cell supernatants were measured by ELISA according to the manufacturer's protocol (eBioscience). The plate was read at 450 nm on a Spectramax 340PC microplate spectrophotometer (Molecular Devices). All samples were run in duplicate.
Statistical analysis
Statistical analysis was performed using Student's unpaired ttest (two-tailed). One-way analysis of variance was used to analyze the MTT experiment. P values less than 0.05 were considered statistically significant. Figure 1) . 33 Without stimulation, there were no significant changes in macrophage or mesangial cell proliferation over time (data not shown). When J774A.1 macrophages were stimulated with LPS/IFN-c, there was a significant increase in the number of let-7a-transfected cells over time compared to the control ( Figure 1a) . Similarly, there was a significant increase in the proliferation of stimulated let-7a-transfected MES 13 mesangial cells over time compared to the control (Figure 1b) .
Cell cycle distribution was measured using flow cytometry post-transfection. In non-stimulated J774A.1 macrophages, let-7a did not cause any significant changes to cell cycle distribution compared to controls either 24 h (data not shown) or 48 h post-transfection (Figure 1c) . In macrophages stimulated with LPS/IFN-c for 24 h, there were no differences in cell cycle distribution between untransfected macrophages or macrophages transfected with let-7a or the non-targeting control miRNA (data not shown). After 48 h of stimulation, there was a significant decrease in the number of let-7a-transfected macrophages in G 1 phase and a significant increase in the number of let-7a-transfected cells in S and M phase compared to the control (Figure 1d ). In non-stimulated MES 13 mesangial cells, cell cycle distribution was unchanged 24 h (Figure 1e ) or 48 h post-transfection (data not shown). After 24 h of stimulation, there was a significant decrease in the number of stimulated let-7a transfected cells in G 1 phase compared to the controls, with a concomitant increase in the number of these cells in S and G 2 phases (Figure 1f ). G 2 distribution remained significantly higher after 48 h of stimulation (data not shown, P,0.05). These data indicate that let-7a promotes stimulated cell proliferation by inducing cell cycle progression through S and G 2 phases.
Let-7a increases Rb phosphorylation
Since we observed increased proliferation in cells overexpressing let-7a, we sought to determine the mechanism by which let-7a induces cell cycle entry. The E2F family of transcription factors plays a major role in the G 1 -S transition in the cell cycle. Hyperphosphorylated Rb releases E2F activators to transcribe genes whose products are important in cell cycle progression. Due to differing states of phosphorylation, different sites of phosphorylation, and different stoichiometries, total Rb can appear as one or two bands in western blotting. [47] [48] [49] In order to verify that let-7a induces E2F activation by increasing Rb phosphorylation (pRb), we measured pRb by western blot in immune-stimulated cells post-miRNA transfection. Untransfected (U) cells and cells transfected with a non-targeting control miRNA (NC) served as the controls. In non-stimulated J774A.1 macrophages, there were no differences in pRb between untransfected macrophages or macrophages transfected with let-7a (L) or the non-targeting control miRNA (Figure 2a and Supplementary Figure 2) . In macrophages transfected with let-7a, there was an increase in pRb compared to the stimulated controls. pRb was undetectable in non-stimulated MES 13 mesangial cells ( Figure 2B and Supplementary Figure 3 ). There was a marked increase in pRb in immune-stimulated mesangial cells overexpressing let-7a.
While it has been established that IL-6 increases pRb, we recently showed that let-7a overexpression increases IL-6 production. 33, 49 To confirm that let-7a-mediated phosphorylation of Rb is facilitated by IL-6, cells were treated with recombinant IL-6 and pRb was measured by western blot. Cells were treated with IL-6 for 1 h due to previous reports that have shown that phosphorylated Rb is predominant at this time. 49 Compared to non-stimulated cells, J774A. Figure 6 ). Compared to the stimulated control, there was a decrease in pRb when let-7a and si-IL-6 were cotransfected in J774A.1 macrophages. There was a slight decrease in pRb in macrophages cotransfected with the non-targeting control miRNA and si-IL-6. Similarly, there was a marked increase in pRb in MES 13 mesangial cells that were stimulated compared to non-stimulated cells (Figure 2h and Supplementary Figure 7) . There was a decrease in pRb in MES 13 mesangial cells cotransfected with let-7a and si-IL-6 Let-7a promotes proliferation and NFkB activation in vitro CB Chafin et al compared to the stimulated controls. These results show that let-7a increases E2F activation by increasing pRb and mediates Rb phosphorylation via IL-6 in stimulated cells.
Let-7a alters the expression of the E2F family of transcription factors Next, we sought to determine if let-7a alters the expression of cell cycle regulators. We used independent computational programs as previously described to predict potential miRNA targets that may be involved in the G 1 -S transition. 33 Let-7a was predicted to target the E2F transcription factor family, which has conserved let-7a binding sites in their 39 UTRs. We measured E2F expression in immune-stimulated cells post-transfection in order to determine the effects of overexpressed let-7a. J774A.1 macrophages and MES 13 mesangial cells were transfected with let-7a (L) or the non-targeting control miRNA (NC) and stimulated with LPS/IFN-c 24 h post-transfection. Real time RT-PCR was used to measure E2F expression. Western blot was used to measure post-transcriptional modifications to E2F expression. Expression of the cell cycle activator E2F2 was significantly increased in immune-stimulated J774A.1 macrophages transfected with let-7a compared to the control (Figure 3a) . Western blot showed there was a decrease in E2F2 in non-stimulated macrophages transfected with let-7a (Figure 3b and Supplementary Figure 8) . However, when let-7a-transfected macrophages were immune-stimulated, E2F2 was unchanged compared to the stimulated controls. This is consistent with our previous work that showed the effect of let-7a on the target mRNA is altered upon immune stimulation. 33 Expression of the cell cycle inhibitor E2F5 was significantly decreased in let-7a-transfected macrophages that were immune-stimulated (Figure 3c ). Western blot showed there was a decrease in E2F5 in non-stimulated or stimulated macrophages transfected with let-7a (Figure 3d and Supplementary Figure 9 ). In MES 13 mesangial cells, E2F2 expression was significantly increased in stimulated cells transfected with let-7a compared to the control (Figure 3e ). E2F2 was decreased in non-stimulated mesangial cells transfected with let-7a (Figure 3f and Supplementary Figure 10) . Like J774A.1 macrophages, E2F2 was unchanged in let-7a-transfected mesangial cells that were stimulated compared to stimulated controls. E2F5 expression was significantly decreased in immune-stimulated, let-7a-transfected mesangial cells (Figure 3g ). Western blot showed that there was a decrease in E2F5 in non-stimulated or stimulated cells (Figure 3h and Supplementary Figure 11) . Taken together, these results indicate that stimulated cells overexpressing let7a have decreased E2F5 expression and reduced E2F5 production. The increase in E2F2 expression in stimulated cells overexpressing let-7a does not result in increased production of E2F2.
The let-7a promoter is regulated by E2F2
We next examined potential transcription factors with binding sites in the let-7a promoter. We used computational analysis to identify putative binding sites for different transcription factors 1-kb upstream of the let-7a start sequence due to previous reports that 1-kb upstream is sufficient to induce promoter activity.
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E2F2 was selected for further analysis in let-7a-mediated cell proliferation after binding sites upstream of the let-7a start site were identified. We measured E2F2 bound to let-7a promoter-enriched DNA post-stimulation using real-time RT-PCR and normal rabbit IgG as the control antibody. After ChIP, there were no differences in promoter binding in non-stimulated J774A.1 macrophages with either the control or E2F2 antibody (Figure 4a ). Compared to the non-stimulated control, there was an increase in E2F2 binding to DNA enriched for the let-7a promoter in macrophages stimulated with LPS/IFN-c. Likewise, there were no differences in promoter binding in non-stimulated MES 13 mesangial cells with either the control or E2F2 antibody (Figure 4b ). There was a significant increase in E2F2 binding to let-7a promoter-enriched DNA post-stimulation.
Because the let-7a promoter contains binding sites for E2F2, we next examined if knockdown of E2F2 altered let-7a expression in stimulated cells. Untransfected cells and cells transfected with a non-targeting siRNA served as the controls. Transfection of si-E2F2 significantly decreased E2F2 expression in immune-stimulated J774A.1 macrophages, confirming transfection efficiency (Figure 4c ). E2F2 expression was also significantly decreased in stimulated MES 13 mesangial cells transfected with si-E2F2 (Figure 4d ). Let-7a expression was significantly decreased when E2F2 was knocked down in immune-stimulated macrophages (Figure 4e ) and mesangial cells (Figure 4f) . In order to determine if IL-6 production is decreased by knocking down E2F2, we measured IL-6 production by ELISA. IL-6 was undetectable in non-stimulated cells (Figure 4g ). With LPS/IFN-c stimulation, IL-6 was significantly decreased in immune-stimulated J774A.1 macrophages after transfection with si-E2F2. IL-6 production was also significantly decreased when E2F2 was knocked down in stimulated MES 13 mesangial cells (Figure 4h ). These results indicate that the let-7a promoter is regulated by E2F2 in stimulated cells.
Let-7a increases NFkB translocation in immune-stimulated cells
Since LPS/IFN-c stimulation activates NFkB via the canonical pathway, we measured let-7a-induced NFkB p65 translocation by western blot. Non-stimulated (NS) cells, untransfected (U) cells, and cells transfected with a non-targeting control miRNA (NC) served as the controls. We chose to measure the nuclear translocation of NFkB 15, 30 and 60 min post-stimulation due to previous reports that have indicated the phosphorylation of IkB returns to baseline levels after 60 min of immune stimulation. 51 There was a slight increase in NFkB activation 30 min post-stimulation in let-7a-transfected (L) J774A.1 macrophages compared to the non-targeting control (Figure 5a and Supplementary Figure 12) . After 15 or 60 min of stimulation, there were no differences in NFkB translocation in macrophages transfected with let-7a compared to the control miRNA. Compared to macrophages transfected with let-7a or the control miRNA, NFkB activation was faster in stimulated macrophages that were not transfected. We next measured phosphorylated IkB by western blot. pIkB was undetectable in macrophages stimulated with LPS/IFN-c for 15 minutes (Figure 5b and Supplementary Figure 13 ). There was a slight increase in pIkB in let-7a-transfected cells stimulated for 30 min, which corresponds to increased NFkB translocation at this time point. By 60 min of immune stimulation, there was a decrease in IkB phosphorylation in macrophages transfected with let-7a compared to the control miRNA. Next we quantified let-7a-induced NFkB p65 translocation by ELISA. NFkB was undetectable in non-stimulated J774A.1 macrophages. As expected, NFkB activation was significantly increased in macrophages compared to the control after 30 min of immune stimulation (Figure 5c ). There were no significant Let-7a promotes proliferation and NFkB activation in vitro CB Chafin et al differences in NFkB activation 15 or 60 min post-stimulation compared to the transfected control.
When MES 13 mesangial cells were analyzed by western blot, there was a slight increase in NFkB p65 translocation in let-7a-transfected cells that were immune-stimulated for 15 minutes (Figure 5d and Supplementary Figure 14) . There were no differences in NFkB translocation at 30 or 60 min. We next measured phosphorylated IkB by western blot. In mesangial cells stimulated for 15 min, there was an increase in pIkB in let7a transfected cells, which is consistent with increased nuclear NFkB translocation at that time (Figure 5e and Supplementary Figure 15) . pIkB was unchanged in cells stimulated for 30 or 60 min. When NFkB p65 activation was quantified by ELISA, there was a significant increase after 15 minutes (Figure 5f ). There were slight yet insignificant increases in NFkB translocation at 30 and 60 min in let-7a-transfected cells. NFkB was undetectable in non-stimulated mesangial cells. Taken together, these data indicate that immune-stimulated cells overexpressing let-7a have increased NFkB activation compared to controls.
The let-7a promoter is regulated by NFkB It has recently been reported that the let-7a promoter contains NFkB binding sites that are highly responsive to the p65 subunit. 50 Computational analysis verified putative binding sites for NFkB 1-kb upstream of the let-7a start sequence. We measured NFkB bound to let-7a promoter-enriched DNA after 15, 30 and 60 min of immune stimulation using real time RT-PCR and normal rabbit IgG as the control antibody. In macrophages immune-stimulated for 30 or 60 min, there was a significant increase in NFkB binding in DNA enriched for the let-7a promoter (Figure 6a) . In mesangial cells, there was a significant increase in NFkB binding after 60 min of immune stimulation (Figure 6b ). These data are consistent with previous reports that have shown increased NFkB binding to the let-7a promoter after 60 min of stimulation. 13 We next examined if knockdown of NFkB p65 alters let-7a expression in stimulated cells. Untransfected cells and cells transfected with a non-targeting siRNA served as the controls. Transfection of si-NFkB significantly decreased NFkB p65 expression in immune-stimulated J774A.1 macrophages (Figure 6c ) and MES 13 mesangial cells (Figure 6d) , confirming transfection efficiency. Let-7a expression was significantly decreased when NFkB was knocked down in stimulated macrophages (Figure 6e ). There was also a significant decrease in let7a expression in stimulated mesangial cells (Figure 6f ). These results confirm that the let-7a promoter is regulated by NFkB in immune-stimulated cells.
Several studies have shown that NFkB is an important mediator of IL-6 transcription. 52, 53 In order to confirm that knocking down NFkB p65 decreases the production of IL-6, we measured IL-6 production by ELISA. IL-6 was undetectable in non-stimulated J774A.1 macrophages (Figure 6g ). IL-6 was significantly decreased in immune-stimulated J774A.1 macrophages after transfection with si-NFkB p65. In nonstimulated MES 13 mesangial cells, IL-6 production was undetectable (Figure 6h ). IL-6 production was also significantly decreased when NFkB p65 was knocked down in LPS/ IFN-c-stimulated MES 13 mesangial cells.
DISCUSSION
One hallmark of SLE is cell proliferation due to inflammatory stimuli. [54] [55] [56] Mesangial proliferation is one of the distinctive histological features of LN, which affects up to 70% of SLE patients. 57, 58 MiRNAs may contribute to LN pathogenesis by altering cell proliferation, proinflammatory mediator production, innate immune cell responses, and Toll-like receptor and NFkB signaling pathways. In SLE, let-7a is overexpressed in renal tissue and mesangial cells and may contribute to elevated IL-6 production. 33, 36 In these studies, we provide evidence that let-7a overexpression increases cell proliferation by increasing E2F activation though IL-6-mediated Rb phosphorylation. Cells overexpressing let-7a have increased expression of the cell cycle activator E2F2 and decreased expression of the repressor E2F5. Let-7a post-transcriptionally modifies E2F5 expression, promoting cell cycle entry. NFkB activation is increased in immune-stimulated cells overexpressing let-7a. In addition, our results indicate that the let-7a promoter is regulated by E2F2 and NFkB. In stimulated macrophages or mesangial cells, knocking down E2F2 or NFkB significantly decreased let-7a expression and IL-6 production.
Our results indicate that inflammation activates a positive feedback loop linking NFkB activation, let-7a overexpression, IL-6 production, and E2F-mediated cell proliferation. We propose the following autocrine signaling pathway that induces stimulated cells overexpressing let-7a to proliferate and increase cytokine production. When an immune complex binds to its receptor, the canonical NFkB pathway is initiated through IkB phosphorylation, enabling NFkB to translocate to the nucleus and transcribe genes including let-7a (among others). 50, 59 Let-7a is continually transcribed due to perpetual NFkB translocation in the proinflammatory environment of SLE. Increased let-7a expression perpetuates the inflammatory response by increasing IL-6 production, which further increases the activation of NFkB. 33 Increased IL-6 production also increases cell proliferation; IL-6 promotes the phosphorylation of Rb via activation of the JAK/STAT pathway. 60 Phosphorylated Rb releases E2F to transcribe genes that are fundamental to cell cycle progression as well as let-7a. 61 By increasing IL-6-mediated Rb phosphorylation, increased let7a expression can contribute to increased cell proliferation.
While it has recently been shown that the expression of let-7a has major implications on cancer cell proliferation, the precise outcomes of overexpressed let-7a in SLE are still being elucidated. [62] [63] [64] [65] In these studies, we demonstrate that cells overexpressing let-7a have decreased expression and production of the repressor E2F5. Because the 39 UTR of E2F transcripts contain potential binding sites for let-7a, let-7a may be directly targeting E2F mRNA, leading to altered protein production. 66 Conversely, let-7a may indirectly modify E2F expression by targeting upstream signaling cascades. Overall, the current studies indicate that let-7a overexpression in immunestimulated cells increases E2F-mediated cell proliferation via IL-6-induced Rb phosphorylation. Increased mesangial cell proliferation leads to an increase in extracellular matrix deposition, which results in a reduced rate of glomerular filtration due to the loss of functioning nephrons. 19 Because let-7a is overexpressed in various tissues and cell types in SLE, increased let7a expression may contribute to increased cell proliferation and the resulting increase in extracellular matrix deposition that are characteristic of the disease. 
